Clinical Results of the MINIject Implant for Suprachoroidal Drainage

This retrospective study evaluated the safety and efficacy of the new minimally invasive MINIject implant placed in the suprachoroidal space. The aim was to assess its impact on intraocular pressure (IOP) reduction and complication rate. 18 eyes from 18 patients with insufficiently controlled glaucoma received the implant using topical medications. Outcomes were changes in IOP, change in IOP medication, need for other glaucoma surgery, and rate of adverse events. IOP reduced by 15% ( < 0.05) following MINIject implantation. IOP medication decreased from 3 to 1 agent ( < 0.05). Four patients (22%) required other glaucoma surgery while we did not observe any clinically relevant adverse event. This retrospective study indicates that MINIject implants may be a safe and effective means of reducing IOP together with a reduction in IOP medications in most patients. Larger prospective studies with longer follow-ups are necessary to confirm our results, though.